Related Experiment Video
Updated: Jan 17, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
[Progress in the application of JAK inhibitors in atopic dermatitis]
1Department of Allergy and Clinical Immunology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009,China.
Abstract:
Atopic dermatitis is a chronic recurrent inflammatory skin disorder associated with heterogenous presentation and immense patient burden. Previous therapeutic drugs include topical glucocorticoids, topical calcineurin inhibitors, oral antihistamines, systemic immunosuppressants, glucocorticoids and biologcis, etc. In recent years, a variety of small molecule drugs have been approved for the treatment of atopic dermatitis.Two selective JAK inhibitors Upadacitinib and Abrocitinib, have been approved for AD treatment indications in China. This mini-review summarizes the clinical application of these two drugs in the treatment of AD, including the underlying molecular mechanisms, clinical trials, and clinical experiences, highlighting the value of selective JAK inhibitors in AD therapy.
More Related Videos
Related Concept Videos
The JAK-STAT Signaling Pathway
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

